Literature DB >> 11887267

The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice.

P Morrison1, D Gaskill, T Meehan, P Lunney, G Lawrence, P Collings.   

Abstract

Forty-four mental health clients completed the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS)--a self-rating scale to assess the prevalence and intensity of neuroleptic side-effects. In the month prior to the study, 50% of the clients surveyed had experienced more than half of the side-effects outlined on the 41-item scale. A prevalence profile allowed us to rank the frequency of individual side-effects across the sample. Some side-effects such as 'difficulty concentrating', 'difficulty remembering', 'tiredness' and 'restlessness' were experienced by most of the clients in the study while 'unusual skin marks', 'difficulty passing water', 'rashes' were experienced by a few. A prevalence profile may be a useful guide in developing strategies for managing side-effects more effectively in small groups of clients. In addition, the use of the LUNSERS in clinical practice would enable case managers to establish baseline measures for individual clients and evaluate changes in medication and other non-medical strategies for reducing unwanted side-effects. The identification and assessment of antipsychotic side-effects is an important area for client and professional carer education.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11887267     DOI: 10.1046/j.1440-0979.2000.00181.x

Source DB:  PubMed          Journal:  Aust N Z J Ment Health Nurs        ISSN: 1324-3780


  7 in total

1.  Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey.

Authors:  John A Bates; Richard Whitehead; Susan C Bolge; Edward Kim
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective.

Authors:  Michela Nosè; Maria Angela Mazzi; Eleonora Esposito; Marco Bianchini; Paola Petrosemolo; Giovanni Ostuzzi; Michele Tansella; Corrado Barbui
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-28       Impact factor: 4.328

3.  Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study.

Authors:  Merhawi Bahta; Tzeggai Berhe; Mulugeta Russom; Eyasu H Tesfamariam; Azieb Ogbaghebriel
Journal:  Integr Pharm Res Pract       Date:  2020-10-14

4.  A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics.

Authors:  Kim Usher; Tanya Park; Kim Foster; Petra Buettner
Journal:  J Adv Nurs       Date:  2012-09-14       Impact factor: 3.187

5.  Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications.

Authors:  Pierre-Michel Llorca; Christophe Lançon; Ann Hartry; T Michelle Brown; Dana B DiBenedetti; Siddhesh A Kamat; Clément François
Journal:  BMC Psychiatry       Date:  2017-02-13       Impact factor: 3.630

6.  Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.

Authors:  Michela Nosè; Simone Accordini; Paola Artioli; Francesco Barale; Corrado Barbui; Rossella Beneduce; Domenico Berardi; Gerardo Bertolazzi; Bruno Biancosino; Alfredo Bisogno; Raffaella Bivi; Filippo Bogetto; Marianna Boso; Alberto Bozzani; Piera Bucolo; Marcello Casale; Liliana Cascone; Luisa Ciammella; Alessia Cicolini; Gabriele Cipresso; Andrea Cipriani; Paola Colombo; Barbara Dal Santo; Michele De Francesco; Giorgio Di Lorenzo; Walter Di Munzio; Giuseppe Ducci; Arcadio Erlicher; Eleonora Esposito; Luigi Ferrannini; Farida Ferrato; Antonio Ferro; Nicoletta Fragomeno; Vincenzo Fricchione Parise; Maria Frova; Francesco Gardellin; Nicola Garzotto; Andrea Giambartolomei; Giancarlo Giupponi; Luigi Grassi; Natalia Grazian; Lorella Grecu; Gualtiero Guerrini; Francesco Laddomada; Ermanna Lazzarin; Camilla Lintas; Francesca Malchiodi; Lara Malvini; Livio Marchiaro; Alessandra Marsilio; Massimo Carlo Mauri; Antonio Mautone; Marco Menchetti; Giuseppe Migliorini; Marco Mollica; Daniele Moretti; Serena Mulè; Stylianos Nicholau; Flavio Nosè; Guglielmo Occhionero; Anna Maria Pacilli; Stefania Pecchioli; Mauro Percudani; Ennio Piantato; Carlo Piazza; Francesco Pontarollo; Roger Pycha; Roberto Quartesan; Luciana Rillosi; Francesco Risso; Raffella Rizzo; Paola Rocca; Stefania Roma; Matteo Rossattini; Giuseppe Rossi; Giovanni Rossi; Alessandra Sala; Claudio Santilli; Giuseppe Saraò; Antonio Sarnicola; Francesca Sartore; Silvio Scarone; Tiziana Sciarma; Alberto Siracusano; Stefania Strizzolo; Michele Tansella; Gino Targa; Annamarie Tasser; Rodolfo Tomasi; Rossana Travaglini; Antonio Veronese; Simona Ziero
Journal:  Trials       Date:  2009-05-15       Impact factor: 2.279

7.  Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: a qualitative study.

Authors:  Flavie Waters; Vivian W Chiu; Aleksandar Janca; Amanda Atkinson; Melissa Ree
Journal:  Front Psychol       Date:  2015-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.